Hyperkalaemia and hypokalaemia outpatient management: a survey of 500 French general practitioners.

Chronic kidney disease/ mineralocorticoid receptor antagonist General practitioners Heart failure Hyperkalaemia Hypokalaemia

Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
10 2020
Historique:
received: 27 01 2020
revised: 15 05 2020
accepted: 27 05 2020
pubmed: 1 7 2020
medline: 22 6 2021
entrez: 1 7 2020
Statut: ppublish

Résumé

How general practitioners (GPs) manage dyskalaemia is currently unknown. This study aimed at describing GP practices regarding hypokalaemia or hyperkalaemia diagnosis and management in their outpatients. A telephone survey was conducted among French GPs with a 20-item questionnaire (16 closed-ended questions and 12 open-ended questions) regarding their usual management of hypokalaemia or hyperkalaemia patients, both broadly and more specifically in patients with heart failure and/or chronic kidney disease and/or in patients treated with angiotensin-converting enzyme/angiotensin receptor blockers or mineralocorticoid receptor antagonists. We aimed to interview 500 GPs spread geographically throughout France. This descriptive survey results are presented as mean ± standard deviation (if normally distributed or as median and inter-quartile range if the distribution was skewed). Categorical variables are expressed as frequencies and proportions (%). A total of 500 GPs participated in the study. Dyskalaemia thresholds (for diagnosis and intervention) and management patterns were highly heterogeneous. The mean ± SD (range) potassium level leading to 'intervene' was 5.32 ± 0.34 mmol/L (4.5-6.5) for hyperkalaemia and 3.23 ± 0.34 mmol/L (2.0-6.5) for hypokalaemia. Potassium levels leading to refer the patient to the emergency department (ED) were 6.14 ± 0.55 (4.5-10) and 2.69 ± 0.42 mmol/L (1-4), respectively. Potassium binders (51-65%) or potassium supplements (67-74%) were frequently used to manage hyperkalaemia or hypokalaemia. GPs uncommonly referred their dyskalaemic patients to cardiologists or nephrologists (or to the emergency department, if the latter was deemed necessary owing to the severity of the dyskalaemia). We identified an association between the close vicinity of GP office from an ED and 'referring a heart failure patient' (19.2% with ED vs. 8.6% without ED) and referring a heart failure and chronic kidney disease patient on mineralocorticoid receptor antagonist (16.7% with ED vs. 9.3% without ED). Although the majority (67%) of GPs had an electrocardiogram on hand, it was rarely used (14%) in dyskalaemic patients. Subgroup analyses considering gender, age of the participating GPs, and high-income/low-income regions did not identify specific patterns regarding the multidimensional aspect of dyskalaemia management. Owing to the considerable heterogeneity of French GP practices toward dyskalaemia diagnosis and management approaches, there is a likely need to standardize (potentially enabled by therapeutic algorithms) practices.

Identifiants

pubmed: 32602236
doi: 10.1002/ehf2.12834
pmc: PMC7524073
doi:

Substances chimiques

Potassium RWP5GA015D

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2042-2050

Subventions

Organisme : Lorraine Université d'Excellence
ID : ANR-15-IDEX-04-LUE
Pays : International
Organisme : RHU Fight-HF
ID : ANR-15-RHUS-0004
Pays : International

Informations de copyright

© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

Références

Eur J Heart Fail. 2018 Aug;20(8):1217-1226
pubmed: 29667759
BMC Nephrol. 2017 Sep 12;18(1):295
pubmed: 28899351
Eur Heart J Suppl. 2019 Feb;21(Suppl A):A48-A54
pubmed: 30837805
ESC Heart Fail. 2020 Oct;7(5):2042-2050
pubmed: 32602236
Clin J Am Soc Nephrol. 2008 Mar;3(2):324-30
pubmed: 18235147
Eur Heart J. 2005 Aug;26(16):1653-9
pubmed: 15827061
Eur J Heart Fail. 2013 Oct;15(10):1173-84
pubmed: 23978433
J Clin Hypertens (Greenwich). 2019 Jul;21(7):991-1001
pubmed: 31169352
JAMA Intern Med. 2019 Aug 1;179(8):1025-1033
pubmed: 31180477
JAMA Cardiol. 2019 May 1;4(5):428-436
pubmed: 30942845
JAMA. 2012 Jan 11;307(2):157-64
pubmed: 22235086
Lancet. 2019 Mar 9;393(10175):1034-1044
pubmed: 30860029
Clin J Am Soc Nephrol. 2010 Mar;5(3):531-48
pubmed: 20150448
Am J Med. 2015 Dec;128(12):1281-7
pubmed: 26093176
Ann Intensive Care. 2019 Feb 28;9(1):32
pubmed: 30820692
Eur Heart J Cardiovasc Pharmacother. 2018 Jul 1;4(3):180-188
pubmed: 29726985
Circ Heart Fail. 2014 Jan;7(1):43-50
pubmed: 24281136
Resuscitation. 2015 Oct;95:148-201
pubmed: 26477412
JAMA. 2015 Nov 10;314(18):1973-5
pubmed: 26547470
Pharmacol Res. 2016 Nov;113(Pt A):585-591
pubmed: 27693804
Eur J Heart Fail. 2020 Aug;22(8):1402-1411
pubmed: 31919958
Am J Emerg Med. 2000 Oct;18(6):721-9
pubmed: 11043630
Circulation. 2018 Aug 28;138(9):929-944
pubmed: 30354446
Circulation. 2018 Mar 27;137(13):1320-1330
pubmed: 29025765
Eur Heart J. 2017 Jun 21;38(24):1883-1890
pubmed: 28329163
J Am Coll Cardiol. 2009 Apr 14;53(15):e1-e90
pubmed: 19358937
Nephrol Dial Transplant. 2017 Dec 1;32(12):2112-2118
pubmed: 28460113
Clin Kidney J. 2019 Sep 30;13(4):714-719
pubmed: 32905252

Auteurs

Laure Abensur Vuillaume (L)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, Plurithématique 1433, and Inserm 1116 DCAC, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Emergency Department, Centre Hospitalier Régional Metz-Thionville, Metz, France.

Patrick Rossignol (P)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, Plurithématique 1433, and Inserm 1116 DCAC, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Zohra Lamiral (Z)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, Plurithématique 1433, and Inserm 1116 DCAC, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Nicolas Girerd (N)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, Plurithématique 1433, and Inserm 1116 DCAC, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Jean-Marc Boivin (JM)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, Plurithématique 1433, and Inserm 1116 DCAC, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH